THE NATURAL HISTORY OF PNEUMOTHORAX ASSOCIATED WITH CARDIAC IMPLANTABLE ELECTRONIC DEVICES - A 10-YEAR SINGLE CENTRE EXPERIENCE

2020 ◽  
Vol 36 (10) ◽  
pp. S54-S55
Author(s):  
G. Thomas ◽  
S. Kumar ◽  
S. Singh
2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Teresa Strisciuglio ◽  
Giuseppe Ammirati ◽  
Valerio Pergola ◽  
Lucio Addeo ◽  
Antonio Rapacciuolo

Abstract Aims Mood disorders are common in patients with cardiac implantable electronic devices (CIEDs). The COVID-19 pandemic may have further undermined their emotional well being exacerbating physical symptoms such as palpitations. We investigated the occurrence of anxiety and palpitations in CIEDs patients during the pandemic. In those with remote monitoring (RM) available, we evaluated whether these symptoms were associated with arrhythmic events. Methods and results The generalized anxiety disorder (GAD) 7-items questionnaire and the frequency of palpitations were assessed by telephonic interview. Overall 152 CIEDs patients agreed to be interviewed (119 males, age 69 ± 14 years). The RM was available in 54/152 (36%). Thirty-seven (24%) and 43 (28%) patients had anxiety and palpitations, respectively, and 23 (15%) patients had both. Women were more likely to have symptoms than men (50% vs. 20%; P < 0.01 for anxiety and 53% vs. 24%; P < 0.01 for palpitations). Among patients with palpitations the RM was available in 17/43 (40%) and revealed true arrhythmic events in 7/17 (41%) patients: eight non-sustained ventricular tachycardias (NSVT), two supra-ventricular tachycardias (SVT), four sustained ventricular tachycardias (VT). The RM enabled to detect in six patients a device malfunctioning: in two increased impedance in the shock lead, in three increased capture threshold for the LV lead and in one the battery reached the end of life. Conclusions Patients with CIEDs were likely to experience anxiety and palpitations during the COVID-19 outbreak and the RM has been pivotal to ascertain the occurrence of arrhythmic events and device malfunctioning in symptomatic and asymptomatic patients as well.


2018 ◽  
Author(s):  
Sergios Gargalas ◽  
Lia Anguelova ◽  
Christine May ◽  
Jane Halliday ◽  
Simon Cudlip ◽  
...  

Heart ◽  
2015 ◽  
Vol 101 (Suppl 5) ◽  
pp. A6-A7
Author(s):  
N Ryan ◽  
N Mahon ◽  
K Walsh ◽  
J O’Neill ◽  
E Keelan ◽  
...  

Haemophilia ◽  
2011 ◽  
Vol 18 (2) ◽  
pp. 166-174 ◽  
Author(s):  
A. TAGLIAFERRI ◽  
C. DI PERNA ◽  
F. RICCARDI ◽  
C. PATTACINI ◽  
G. F. RIVOLTA ◽  
...  

2013 ◽  
Author(s):  
Panagiotis Anagnostis ◽  
Zoe Efstathiadou ◽  
Chrisanthi Zouli ◽  
Albana Soukia ◽  
Athanasios Panagiotou ◽  
...  

2019 ◽  
Vol 50 (11-12) ◽  
pp. 1172-1180 ◽  
Author(s):  
Emanuela Miceli ◽  
Alessandro Vanoli ◽  
Marco Vincenzo Lenti ◽  
Catherine Klersy ◽  
Michele Di Stefano ◽  
...  

Medicina ◽  
2019 ◽  
Vol 55 (10) ◽  
pp. 611 ◽  
Author(s):  
AlTurki ◽  
Marafi ◽  
Russo ◽  
Proietti ◽  
Essebag

Subclinical atrial fibrillation (SCAF) describes asymptomatic episodes of atrial fibrillation (AF) that are detected by cardiac implantable electronic devices (CIED). The increased utilization of CIEDs renders our understanding of SCAF important to clinical practice. Furthermore, 20% of AF present initially as a stroke event and prolonged cardiac monitoring of stroke patients is likely to uncover a significant prevalence of SCAF. New evidence has shown that implanting cardiac monitors into patients with no history of atrial fibrillation but with risk factors for stroke will yield an incidence of SCAF approaching 30–40% at around three years. Atrial high rate episodes lasting longer than five minutes are likely to represent SCAF. SCAF has been associated with an increased risk of stroke that is particularly significant when episodes of SCAF are greater than 23 hours in duration. Longer episodes of SCAF are incrementally more likely to progress to episodes of SCAF >23 hours as time progresses. While only around 30–40% of SCAF events are temporally related to stroke events, the presence of SCAF likely represents an important risk marker for stroke. Ongoing trials of anticoagulation in patients with SCAF durations less than 24 hours will inform clinical practice and are highly anticipated. Further studies are needed to clarify the association between SCAF and clinical outcomes as well as the factors that modify this association.


Sign in / Sign up

Export Citation Format

Share Document